ARIAD Pharmaceuticals Inc
Most Recent
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
What Sprycel Could Mean for Bristol-Myers Squibb
In 2016, Bristol-Myer Squibb’s (BMY) Sprycel reported revenues of ~$1.8 billion, which represents a ~13% YoY rise.
Why These Collaborations Are Important to Incyte
Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.
What’s in Incyte’s Product Portfolio?
Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
Incyte’s Profitability Improves, Allowing for Revised Guidance
Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.
Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.
How Could the Novartis-Xencor Alliance Benefit Novartis?
As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.
